New transplant method aims to reduce dangerous side effects in blood cancer patients
NCT ID NCT05617625
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a special stem cell transplant that removes immune T-cells from the donor's blood to lower the risk of graft-versus-host disease (GVHD), a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic syndrome (a blood cancer) will receive chemotherapy followed by the processed transplant. The study is currently suspended, and its main goal is to see if this method reduces GVHD severity and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD34+ enriched, T-cell depleted stem cell transplant using the CliniMACS system
- What this could lead to
- If successful, this approach could reduce the severity of graft-versus-host disease after stem cell transplants, improving outcomes for patients with myelodysplastic syndrome.
- What could go wrong
- This is a small, early-phase trial that is currently suspended. The procedure carries risks including infection, organ damage, and transplant failure, and it may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Miami Cancer Institute
Miami, Florida, 33176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?